Our Management Team

Untitled design-39

Guy Yachin

Head Of US Site

2

Dr. Mark Spear

Head Of Preclinical Unit US

Dr. Sam Agus M.D

Medical Director

Dr. Udi Gluschnaider

Head of Sales and Business Development

Dr. Perri Rozenberg - Hasson

Head of Pre-clinical Unit

Dr. Eddy Pichinuk

Chief Technology Officer

Fabian Arditti

Dr. Fabian Arditti

Business Development Advisor

13 YEARS OF GLP ACCREDITATION

Shmuel Landau

co-CEO

Shmuel Landau brings over 30 years of experience in general and financial management, as well as business consulting, to his role as co-CEO. His tenure, marked by driving sales growth, enhancing profitability, and leading successful turnarounds, showcases his commitment to results and strategic leadership.

His expertise encompasses leadership, innovation, team building, and the management of diverse teams both locally and internationally. Shmuel holds a BA in Accounting and Economics from Tel Aviv University, is a certified CPA in Israel, and has obtained certifications in Information Technologies Analysis.

Shmuel’s approach is defined by a pragmatic focus on tangible outcomes and operational efficiency, underpinned by his extensive educational background and professional certifications. His leadership is instrumental in navigating our organization through growth and challenges, positioning us for success in a competitive global landscape.

Dr. Itschak Lamensdorf

Dr. Itschak Lamensdorf

Founder & CEO

Dr. Lamensdorf, who founded Pharmaseed in 2003, has been responsible for its scientific expansion, national and international collaborations and staff excellence. He was the founder and CEO of PharmaSense in 2001, a biotechnology company that specialized in the treatment of CNS disorders.

Dr. Lamensdorf holds a PhD in Pharmacology from the Faculty of Medicine of the Technion, Israel Institute of Technology, and a BSc and MSc in Clinical Pharmacy from the Hebrew University of Jerusalem Medical School.

He held post-doctoral training programs at the National Institute of Neurological Disorders and Stroke of the National Institute of Health (NIH), Bethesda, Maryland and at the Molecular Genetics Department of Israel’s Weizmann Institute of Science. 

BSC+ LEVEL RESEARCH ASSISTANTS

Guy Yachin

Head Of US Site

Entrepreneur and CEO of multiple biomedical companies; raised over $80MM as CEO and Co-founder of Chiasma (Nasdaq:CHMA) and MGVS, which he led through a mega-deal with Teva Pharmaceuticals; Has been an active board member in Orgenesis (Nasdaq:ORGS), Enzymotec (Nasdaq:ENZY), Remon Technologies (acquired by Boston Scientific), Serpin Pharma and others.

Dr. Mark Spear


Head of Pre-Clinical Unit US

Sam Agus M.D

Medical Director

Dr. Agus is a board-certified neurologist and a seasoned medication and device (including software as medical device) development expert, with more than 20 years of global experience in multiple therapy areas. 

Served as Chief Medical Officer with several biotech companies and as a senior leader in clinical development and medical affairs in mid-size and large pharmaceutical companies.

Dr. Udi Gluschnaider

Head of Sales and Business Development

Dr. Udi Gluschnaider is the Head of Sales and Business Development at Pharmassed, having joined the team in 2024. He holds a PhD in Medical Science and a Bachelor’s degree in Animal Science from the Hebrew University, where he also completed his post-doctoral training in Cancer Metabolism.

Throughout his career, Dr. Gluschnaider has held significant roles, including project manager positions at Aposense, LogicBio, Ayala Pharmaceuticals, and Chemomab. Before his current role at Pharmassed, he served as the Director of Preclinical Development at Chemomab Therapeutic. Dr. Gluschnaider brings extensive experience in cancer biology, genetics, gene therapy, imaging, diagnostics, and both in vitro and in vivo models to his role.

His background equips him with a deep understanding of the scientific and business aspects of the pharmaceutical industry, enabling him to lead sales and business development strategies effectively.

Beyond his expertise, Dr. Gluschnaider finds balance in life as an avid marathon runner. This dedication to fitness complements his sharp mind for study design and problem-solving, skills that have greatly contributed to his professional achievements. His commitment to both intellectual pursuits and physical well-being underscores his well-rounded approach to life.

Dr. Perry Rozenberg - Hasson

Director of In-Vitro uint

Dr. Perri Rozenberg-Hasson joined the Preclinical Research & Development unit of Pharmaseed in 2018 as a Study Director and has served as the Director of the In-Vitro unit since September 2019.

Perri holds a Ph.D. degree in Immunology, a Master’s degree in Cellular Biology, and a Bachelor’s degree in Biology from Tel Aviv University. In her past positions, Perri served as a Teaching Assistant in Immunology, Virology, Microbiology, and Mycology, as well as a Flow Cytometry Analyzer Instructor at Tel Aviv University and a Research assistant at InSight Biopharmaceuticals.

She specializes in various in-vitro assays, primary cell cultures, in-vivo cancer models, and metabolic models. Dr. Rozenberg-Hasson has published numerous scientific papers, mainly concerning the role of eosinophils in cancer, and respiratory and metabolic disorders.

Ronnie Levy
PHD+ LEVEL STUDY DIRECTORS

Prof. Ronnie Levy

CSO

Prof. Ronnie Levy joined Pharmaseed in 2010 as Liaison to Pharmaseed’s Scientific Advisory Board and has been serving as Chief Science Officer since 2015.
Prof. Levy holds a PhD and MSc in Chemistry from The Hebrew University, completed a post-doctoral training in pharmacology at the Roche Institute for Molecular Biology and has a full professor nomination at Ben-Gurion University, Beer-Sheva. Ronnie formerly served as the Head of the Radiochemistry Department at the Nuclear Research Center in the Negev (NRCN) and served at the Israel Institute of Biological Research (IIBR) for 30 years, 13 of which as Head of the Pharmacology Department. He also served on the Board of Directors of the Dead Sea Bromine Group as head of the Research Committee. Prof. Levy attended several sabbaticals during which he conducted research at renowned institutes.
Specializing in biopharmaceuticals, preclinical studies, pharmacokinetics, and new drug development, Prof. Levy has published numerous scientific papers and patents, mainly concerning the development of therapeutic agents for treating central nervous system disorders.

Ronnie’s motto is “being old is only in your mind”. In other words, you should always keep a young spirit. 

Dr. Eddy Pichinuk

Chief Technology Officer

Fabian Arditti
PHD+ LEVEL STUDY DIRECTORS

Dr. Fabian Arditti

VP of Immuno-Oncology & Innovation

Dr. Fabian Arditti joined Pharmaseed’s Preclinical Research & Development Unit in 2013 as a Study Director. In 2015, he joined the Business Development Unit as Director of Immunology & Oncology and in 2017 was promoted to VP of Immunology & Oncology. He also has been serving as Head of Innovation since January 2022. 

Fabian holds a PhD in Immunology from Weizmann Institute of Science, a MSc and BSc in Animal Sciences from The Hebrew University and completed a post-doctoral training in Biochemistry at Weizmann Institute of Science and in The Cancer Center of the Hackensack University Medical Center (HUMC) in NJ, USA. Fabian formerly served as head of Hematology Research Laboratory at Kaplan Medical Center, and as R&D Manager at Capsutech (at the NGT incubator).  

Specializing in planning of diverse (cell-based, small molecules, antibodies, etc.) therapeutic approaches and novel in-vitro and in-vivo models of disease, Dr. Arditti has published numerous scientific papers, mainly concerning cell therapy for treatment of cancer and organ regeneration, and organ transplantation.

Fabian’s motto is “there are a lot of shades of colors”. In other words, he enjoys all types of music, from classic and opera, through Arabic-oriental, rock, and heavy metal.